Thursday, March 30, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

Is Now the Right Time to Stamp Out Measles?

by Global Biodefense Staff
February 12, 2018
Baby hospitalized with measles (rubeola)

Photographed early in 2014 in the Philippines capital city of Manila, this baby was in a hospital with measles (rubeola). Since typhoon Haiyan, the Philippines, especially metropolitan Manila, has been experiencing a large measles outbreak. U.S. Centers for Disease Control and Prevention’s (CDC), Jim Goodson, M.P.H., of the Global Immunization Division in the Center for Global Health, took this photo during his time in Manila, while participating in the response to the measles outbreak. The maculopapular rash on the infant's face, which is one of the hallmark symptoms of this disease. Credit: Jim Goodson, M.P.H.

Before the measles vaccine became available in 1963, there were approximately 3 to 4 million cases, and an average of 450 deaths a year in the U.S., with epidemic cycles occurring every 2 to 3 years. More than half the population had measles by the time they were 6 years old, and 90% had the disease by the time they were 15 years of age. Credit: CDC

In 2016, an estimated 90,000 people died from measles – an 84% drop from more than 550,000 deaths in 2000, according to the World Health Organization.

From The Shadow Crusade to End Measles by Maryn McKenna (Wired):

After the thrill of eradicating smallpox, declared gone from the world in 1980 after a 14-year effort, global health planners dreamed big dreams about the other diseases they would vanquish. But in the years since, eradication efforts stalled. The campaign against Guinea worm has been going since 1980; polio, since 1988; river blindness, in the Americas, since 1992.

Smallpox had been chosen not just because it was a killer, but because it possessed qualities that made eradication plausible. It affected only humans and couldn’t hide in animals or the environment. It produced visible signs of illness, quickly—epidemiologists could easily trace who had infected whom—and its symptoms were unique. And it could be prevented with just one dose of a vaccine.

As it happens, measles fits those conditions too—more so than the other diseases that have been in public health’s sights since. It has no nonhuman host. It can be detected with a reliable diagnostic test. And it can be prevented with a single vaccine dose (though kids in the United States get two childhood doses, just to be sure).

A dark gift of eradication campaigns is that their intense focus on a disease reveals things that research had never recognized before. It wasn’t until the polio campaign began that vaccine-derived polio was even discovered. Years down the line, scientists have realized the mutated virus can be a long-lasting risk. It can reproduce for years in the guts of people with certain immune system disorders, making them permanent emitters of infectious virus that passes into sewage. That’s driven development of new antiviral drugs to give to those long-term excreters, to prevent them from being the disease’s last refuge.

Through nationwide use of vaccination, endemic measles (i.e., a transmission chain lasting 12 months or longer) was eliminated in the United States in 2000. Yet, importations of measles from endemic countries continue to occur, leading to outbreaks. From 2001 to 2015, the overall annual incidence of measles remained extremely low (less than 1 case/million population) compared with incidence worldwide (40 cases/million population); relative increases in measles rates were observed over the period, and the findings suggest that failure to vaccinate may be the main driver of measles transmission, according to a study published by JAMA.

But in an era of vaccine hesitancy and misinformation, even small reductions in childhood measles vaccinations in the U.S. would produce disproportionately large increases in the number of measles cases and in related public health costs. A 5 percent drop in the number of children ages 2 to 11 inoculated against the measles, mumps and rubella would potentially triple the number of annual measles cases in this age group.

The additional measles cases would increase annual public health expenditures by at least $2.1 million, or $20,000 per case of measles, according to the CDC.

Vintage Rubella - Measles Immunization Poster
Shown here is a grouping of four illustrations that were used in public service campaigns to encourage parents to vaccinate their children against Rubella in the late 1960s and early 1970s. Rubella, or more commonly known as the German measles, is a mild childhood illness that can pose a serious threat to a fetus, if the mother contracts the illness during pregnancy. More than 20,000 babies were born with congenital rubella syndrome (CRS) during an outbreak of rubella in 1964-65. This epidemic cost the country an estimated $1.5 billion. The rubella vaccine was first approved in the U.S. in 1969.
Servicemember Receives MMR - Measles, Mumps and Rubella Vaccine
The Tripler Army Medical Center Allergy & Immunizations Clinic’ Sgt. Christopher Hutchins, right, administers the Measles, Mumps, Rubella vaccine to Sgt. 1st Class Chad Williams, left, on Jan. 31, 2018. Credit: Leanne Thomas, TAMC

Related Resources:

  • Measles & Rubella Initiative
  • The History of Vaccines Timeline
  • The Pink Book: Measles
Tags: MeaslesVaccine OppositionVaccines

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Officials Declare End to Ebola Outbreak in Uganda
Infectious Diseases

Officials Declare End to Ebola Outbreak in Uganda

January 11, 2023
Why Upper Respiratory Infectious are More Common in Colder Temperatures
Infectious Diseases

Why Upper Respiratory Infectious are More Common in Colder Temperatures

December 7, 2022
Load More

Latest News

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC